Table 4.
Associations Between Baseline Arsenic Exposure Variables and Plasma Levels of MMP-9, Myeloperoxidase, PAI-1, Soluble E-Selectin, Soluble ICAM-1, and Soluble VCAM-1, by Body Mass Index, Health Effects of Arsenic Longitudinal Study, Bangladesh, 2007–2008a
| Body Mass Index, ≤19.1 | Body Mass Index, >19.1 | Pinteraction | |||||
| No. | Exp (β)b | 95% CI | No. | Exp (β)b | 95% CI | ||
| Baseline well water arsenic, μg/L | 324 | 322 | |||||
| MMP-9 | 1.00 | 0.97, 1.03 | 0.99 | 0.96, 1.02 | 0.33 | ||
| Myeloperoxidase | 0.97 | 0.94, 1.01 | 1.01 | 0.98, 1.05 | 0.45 | ||
| PAI-1 | 0.99 | 0.96, 1.02 | 1.04 | 1.01, 1.08 | 0.03 | ||
| Soluble E-selectin | 0.98 | 0.96, 1.00 | 1.02 | 0.99, 1.05 | 0.09 | ||
| Soluble ICAM-1 | 0.98 | 0.94, 1.01 | 1.03 | 0.99, 1.07 | 0.10 | ||
| Soluble VCAM-1 | 1.00 | 0.99, 1.02 | 1.04 | 1.02, 1.06 | 0.009 | ||
| Baseline urinary arsenic, μg/g creatinine | 325 | 325 | |||||
| MMP-9 | 0.96 | 0.90, 1.04 | 0.98 | 0.91, 1.05 | 0.93 | ||
| Myeloperoxidase | 0.94 | 0.87, 1.02 | 1.00 | 0.93, 1.08 | 0.51 | ||
| PAI-1 | 0.98 | 0.91, 1.04 | 1.12 | 1.04, 1.20 | 0.008 | ||
| Soluble E-selectin | 0.94 | 0.90, 0.99 | 1.05 | 0.99, 1.12 | 0.05 | ||
| Soluble ICAM-1 | 0.94 | 0.87, 1.03 | 1.08 | 0.99, 1.18 | 0.04 | ||
| Soluble VCAM-1 | 0.99 | 0.95, 1.03 | 1.09 | 1.04, 1.13 | 0.002 | ||
Abbreviations: CI, confidence interval; Exp (β), exponentiated regression coefficient; ICAM-1, intercellular adhesion molecule-1; MMP-9, matrix metalloproteinase-9; PAI-1, plasminogen activator inhibitor-1; VCAM-1, vascular adhesion molecule-1.
Models were run with log-transformed MMP-9, myeloperoxidase, PAI-1, soluble E-selectin, soluble ICAM-1, and soluble VCAM-1.
Computed with the log-transformed arsenic level entered as a continuous variable in the linear regression models, adjusting for sex, age (years), education, and smoking status (never vs. ever).